# Phase 16B: PIT Portfolio Validation Handoff

## Objective

Close PIT portfolio validation with a concise interpretation handoff and define practical next directions.

## Completed workflow

The real-data research pipeline has been completed end-to-end for this phase:

1. Real CSI500 feature store build
2. PIT CSI500 universe filtering integration
3. Baseline candidate suite execution
4. Portfolio-level Top50 backtest execution
5. Equal-weight benchmark comparison output

## PIT empirical conclusion

### Benchmark baseline (equal-weight, research benchmark)

- `total_return` ≈ 0.283190 (5bps comparison rows)
- `annualized_return` ≈ 0.082571
- `annualized_vol` ≈ 0.212653
- `sharpe` ≈ 0.388287
- `max_drawdown` ≈ -0.325337

### Strategy vs benchmark

All tested Top50 strategies underperformed equal-weight on a benchmark-relative basis:

- `ret_20d_reversal_top50_weekly`
  - 5bps: `total_return` ≈ 0.047258, `excess_return` ≈ -0.235932
  - 10bps: `total_return` ≈ -0.032875, `excess_return` ≈ -0.314820
- `ret_5d_reversal_top50_weekly`
  - 5bps: `total_return` ≈ 0.092263, `excess_return` ≈ -0.190927
  - 10bps: `total_return` ≈ -0.052580, `excess_return` ≈ -0.334525
- `ret_20d_momentum_top50_weekly`
  - 5bps: `total_return` ≈ 0.227179, `excess_return` ≈ -0.056010
  - 10bps: `total_return` ≈ 0.146547, `excess_return` ≈ -0.135398

### Decision

- No tested baseline is promoted.
- Positive absolute return is insufficient when benchmark-relative evidence is negative.
- Simple return-based Top50 selection currently shows no alpha evidence under PIT validation.
- `ret_20d_momentum` is the least bad among tested variants, but still underperforms equal-weight.
- `ret_5d_reversal` remains highly cost-sensitive.
- Current simple return-factor testing should be paused.

## Why this is still a successful milestone

This is a meaningful success for research infrastructure and process quality:

1. Real-data pipeline execution is stable.
2. PIT universe handling is integrated and functioning.
3. Cost-sensitive portfolio validation is functioning.
4. Benchmark-relative validation is functioning.
5. The system can now reject weak ideas with evidence, which is core to disciplined research.

## Current limitations

1. Equal-weight benchmark is a research benchmark, not the official CSI500 index benchmark.
2. Official CSI500 index benchmark is not yet integrated into this runner.
3. Risk/exposure attribution is not yet included.
4. No industry/size/liquidity neutralization layer is included.
5. No production-grade execution model is included.

## Recommended next-phase options

A. **Pause new factor testing; improve portfolio construction first**
- Focus on selection/weighting/rebalance rule quality before adding new factors.

B. **Add risk/exposure diagnostics**
- Add systematic diagnostics for style/industry/exposure drift and concentration.

C. **Integrate official CSI500 benchmark**
- Add index-level benchmark comparison to complement equal-weight research baseline.

D. **Run broader portfolio-rule comparison**
- Compare TopN/buffer/rebalance/cost interactions more systematically.

E. **Pause quant development and prepare project summary**
- Consolidate findings into a polished project package for resume/interview usage.
